for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Allogene Therapeutics Inc

ALLO.OQ

Latest Trade

11.36USD

Change

-0.22(-1.90%)

Volume

824,607

Today's Range

11.36

 - 

11.85

52 Week Range

11.36

 - 

39.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.58
Open
11.44
Volume
824,607
3M AVG Volume
30.13
Today's High
11.85
Today's Low
11.36
52 Week High
39.08
52 Week Low
11.36
Shares Out (MIL)
142.52
Market Cap (MIL)
1,650.34
Forward P/E
-5.91
Dividend (Yield %)
--

Next Event

Q4 2021 Allogene Therapeutics Inc Earnings Release

Latest Developments

More

Allogene Therapeutics Agreement With Antion Biosciences For Multiplex Micar Technology

Allogene Therapeutics Announces Removal Of FDA Clinical Hold Across All Allocar T Clinical Trials

Allogene Reports FDA Clinical Hold Of AlloCAR T Trials Based On Single Patient Case In Alpha2 Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-715, ALLO-605, ALLO-316, and ALLO-647.

Industry

Biotechnology & Drugs

Contact Info

210 E Grand Ave

SOUTH SAN FRANCISCO, CA

94080-4811

United States

+1.650.4572700

http://www.allogene.com/

Executive Leadership

Arie S. Belldegrun

Executive Chairman of the Board

David Chang

President, Chief Executive Officer, Co-Founder, Director

Joshua A. Kazam

Co-Founder, Director

Eric T. Schmidt

Chief Financial Officer

Rafael G. Amado

Executive Vice President - Research and Development, Chief Medical Officer

Key Stats

1.89 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-7.310

2019

-1.830

2020

-2.080

2021(E)

-1.964
Price To Earnings (TTM)
--
Price To Sales (TTM)
42.93
Price To Book (MRQ)
1.70
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-22.81
Return on Equity (TTM)
-21.78

Latest News

Latest News

Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'

Sluggish U.S. biotech shares could require a wave of deal-making or exciting clinical trial results if the sector wants to join the stock market's party after lagging Wall Street's broad advance this year.

BRIEF-Allogene Therapeutics Announces Pricing Of Public Offering Of Common Stock

* ALLOGENE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Allogene Therapeutics Commences Public Offering Of Common Stock

* ALLOGENE THERAPEUTICS ANNOUNCES COMMENCEMENT OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Allogene Therapeutics, With Collaborator Servier, Reports Positive Results From Its Phase 1 Alpha Study Of Allo-501 In Relapsed/Refractory Non-Hodgkin Lymphoma

* ALLOGENE THERAPEUTICS, WITH COLLABORATOR SERVIER, REPORTS POSITIVE RESULTS FROM ITS PHASE 1 ALPHA STUDY OF ALLO-501 IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

U.S. RESEARCH ROUNDUP-CVS Health, Regal Beloit, Zuora

Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CVS Health, Regal Beloit and Zuora, on Thursday. HIGHLIGHT * CVS Health Corp : Credit Suisse raises to outperform from neutral * Dow Inc : HSBC cuts to hold...

BRIEF-Allogene Therapeutics Expects To Initiate Enrollment In Phase 1 Lymphoma Trial In Q2 2020

* AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ABSTRACT REPORTS INITIAL ALLO-501 ALPHA PHASE 1 DATA IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA

U.S. RESEARCH ROUNDUP-Ashland Global, Lyft, Solaredge Technologies

Wall Street securities analysts on Thursday revised their ratings and price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and Solaredge Technologies. HIGHLIGHTS * Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight...

BRIEF-Allogene Therapeutics Q1 Loss Per Share $0.50

* ALLOGENE THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies

* MAXCYTE AND ALLOGENE THERAPEUTICS SIGN CLINICAL AND COMMERCIAL LICENSE AGREEMENT TO ENABLE THE ADVANCEMENT OF ALLOGENEIC CAR T (ALLOCAR T™) THERAPIES

BRIEF-Allogene Therapeutics Reports Q4 Loss Of $0.58 Per Share

* ALLOGENE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BUZZ-U.S. STOCKS ON THE MOVE-Eventbrite, oil stocks, Big Lots, Exxon Mobil, Costco

* Eikon search string for individual stock moves: * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks were on pace for their fifth day of losses on Friday, after weak U.S. jobs data in February added...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up